(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Oxford BioDynamics PLC on Thursday said it is planning to apply for inclusion into the National Comprehensive Cancer Network clinical guidelines, as it reported the publication of interim results from its FDA-registered Prowes trial. Read More
Oxford BioDynamics PLC - Oxford, England-based biotechnology company that develops medical tests - Announces collaboration with Google Cloud to support the development and deployment of Oxford Biodynamics's analytical framework on the cloud. Google Cloud will provide support via cloud computing, enabling Oxford Biodynamics to scale its proprietary EpiSwitch knowledge space and analytical tools and deliver high-throughput, artificial intelligence-powered 3D genomic analytics in a secure and efficient environment, aimed at helping pharma and biotech partners. Read More
(Alliance News) - Stock prices in Europe were largely higher on Tuesday, setting aside the tariff worries that kept enthusiasm to a minimum at the start of the week. Read More
(Alliance News) - Oxford Biodynamics PLC on Tuesday said its biomarkers were shown to be effective indicators of cancer in trials conducted by Pfizer Inc. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Oxford BioDynamics PLC on Thursday announced an expanded strategic agreement with UK health insurance provider Bupa. Read More
(Alliance News) - Blue-chip stocks in Europe recovered lost ground to end largely higher on Friday afternoon, though the FTSE 100 outperformed. Read More
(Alliance News) - Oxford Biodynamics PLC shares tumbled 10% on Friday, after the firm reported its loss widened in 2024 despite a rise in revenue. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday. Read More
(Alliance News) - European equities traded lower on Friday morning, after Asian stocks sunk on the latest tariff barb by US President Donald Trump. Read More
(Alliance News) - Oxford BioDynamics PLC on Wednesday said it has partnered with Regina Maria Private Health Network, the largest medical services provider in Romania, on the distribution of its blood test products. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday. Read More
Oxford BioDynamics PLC - Oxford, England-based biotechnology company has two blood testing products on market, the PSE prostate cancer screening test and the CiRT checkpoint inhibitor response test - Raises GBP350,000 via retail share offer at 0.5 pence per share. This is in addition to GBP7.0 million raised by placing and subscription at the same price, announced on Wednesday. Read More
Oxford BioDynamics PLC - Oxford, England-based biotechnology company has two blood testing products on market, the PSE prostate cancer screening test and the CiRT checkpoint inhibitor response test - Plans to raise GBP6 million via placing at a minimum price of 0.5 pence per share, a subscription and GBP500,000 cornerstone investment by OAK Securities. Further, seeks to raise GBP500,000 via retail offer. The placing will be conducted through an accelerated bookbuilding process. Proceeds will be used as working capital to support the continued commercial development of the EpiSwitch product line through partnerships and collaborations with diagnostic and pharmaceutical companies and direct sales as appropriate. Read More
(Alliance News) - London's FTSE 100 closed higher on Monday, although bookmakers suffered, as the UK prime minister played down rumours of a capital gains tax hike and urged investors to back his plans for growth. Read More
(Alliance News) - Oxford BioDynamics PLC on Monday launched a strategic review after warning it would need additional cash resources by early 2025. Read More
(Alliance News) - Oxford BioDynamics PLC on Tuesday reported strong revenue growth on the back of the increased commercialisation of its EpiSwitch genomics platform. Read More